Edition:
United States

Organovo Holdings Inc (ONVO.OQ)

ONVO.OQ on NASDAQ Stock Exchange Global Market

1.01USD
23 Feb 2018
Change (% chg)

$-0.02 (-1.94%)
Prev Close
$1.03
Open
$1.03
Day's High
$1.03
Day's Low
$1.00
Volume
72,100
Avg. Vol
272,413
52-wk High
$3.25
52-wk Low
$0.95

Chart for

About

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products,... (more)

Overall

Beta: 2.76
Market Cap(Mil.): $107.99
Shares Outstanding(Mil.): 106.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Organovo Holdings Files For Mixed Shelf Offering Of Up To $100 Mln

* ORGANOVO HOLDINGS INC FILES FOR MIXED SHELF OFFERING OF UP TO $100 MILLION - SEC FILING Source text (http://bit.ly/2EQ7FuR) Further company coverage:

Feb 08 2018

BRIEF-Organovo Reports Q3 Loss Per Share Of $0.07

* ORGANOVO ANNOUNCES FISCAL THIRD-QUARTER 2018 RESULTS; COMPANY UPDATES FULL-YEAR FISCAL 2018 OUTLOOK

Feb 08 2018

BRIEF-Organovo Receives Orphan Designation From U.S. FDA For 3D Bioprinted Therapeutic Liver Tissue

* ORGANOVO RECEIVES ORPHAN DESIGNATION FROM U.S. FDA FOR 3D BIOPRINTED THERAPEUTIC LIVER TISSUE TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY Source text for Eikon: Further company coverage:

Dec 26 2017

BRIEF-Organovo posts Q3 loss per share $0.09

* Organovo announces fiscal second-quarter 2018 results; company shifts commercial focus to higher-value disease modeling opportunities and updates full-year fiscal 2018 outlook

Nov 09 2017

BRIEF-Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

* Organovo and Viscient Biosciences collaborate to develop custom research platform for studying liver disease

Nov 06 2017

Earnings vs. Estimates